A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Open accessThe DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Abstract
Major advances in understanding the pathogenesis of inherited metabolic disease caused by mitochondrial DNA mutations have yet to translate into treatments of proven efficacy. Leber's hereditary optic neuropathy is the most common mitochondrial DNA disorder causing irreversible blindness in young adult life. Anecdotal reports support the use of idebenone in Leber's hereditary optic neuropathy, but this has not been evaluated in a randomized controlled trial. We conducted a 24-week multi-centre double-blind, randomized, placebo-controlled trial in 85 patients with Leber's hereditary optic neuropathy due to m.3460G>A, m.11778G>A, and m.14484T>C or mitochondrial DNA mutations. The active drug was idebenone 900 mg/day. The primary end-point was the best recovery in visual acuity. The main secondary end-point was the change in best visual acuity. Other secondary end-points were changes in visual acuity of the best eye at baseline and changes in visual acuity for both eyes in each patient. Colour-contrast sensitivity and retinal nerve fibre layer thickness were measured in subgroups. Idebenone was safe and well tolerated. The primary end-point did not reach statistical significance in the intention to treat population. However, post hoc interaction analysis showed a different response to idebenone in patients with discordant visual acuities at baseline; in these patients, all secondary end-points were significantly different between the idebenone and placebo groups. This first randomized controlled trial in the mitochondrial disorder, Leber's hereditary optic neuropathy, provides evidence that patients with discordant visual acuities are the most likely to benefit from idebenone treatment, which is safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapy for LHON has been restricted to supportive measures rather than cure.10”
From Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1/2 Clinical Trial (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Current treatments for LHON remain inadequate.8 Idebenone (Raxone, Santhera GmbH) was granted market authorization by the European Medicines Agency (EMA) for the treatment of LHON under exceptional circumstances, 9,10 but its benefits are limited.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Linear mixed models for longitudinal data
(2000) · Springer Series in Statistics · doi:10.1007/b98969 · Cited by 818
Lange, C., Feltgen, N., Junker, B., Schulze-Bonsel, K., & Bach, M. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0926-0 · Cited by 626 · cited 1×
“Patients only able to count fingers, detect hand motion or light perception were assigned logMAR values 2.0, 2.3 and 2.6, respectively (Lange et al., 2009).”
BackgroundInfluentialRiordan-Eva, P., Sanders, M. D., Govan, G. G., Sweeney, M. G., Costa, J. D., & Harding, A. E. (1995) · Brain · doi:10.1093/brain/118.2.319 · Cited by 490
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Man, P. Y. W., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 483 · cited 1×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundSelf-citationNewman, N. J., Lott, M. T., & Wallace, D. C. (1991) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)76784-4 · Cited by 403 · cited 3×
“Most remain legally blind, are unable to drive a motor vehicle, and are unable to find employment (Newman et al., 1991; Riordan-Eva et al., 1995; Nikoskelainen et al., 1996).”
BackgroundResultInfluentialThe epidemiology of mitochondrial disorders—past, present and future
Schaefer, A. M., Taylor, R. W., Turnbull, D. M., & Chinnery, P. F. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.09.005 · Cited by 396 · cited 1×
“Inherited disorders of mitochondrial energy metabolism are a major cause of metabolic disease affecting more than 1/5000 of the population (Schaefer et al., 2004).”
BackgroundSelf-citationBARBONI, P., SAVINI, G., VALENTINO, M., MONTAGNA, P., CORTELLI, P., DENEGRI, A., SADUN, F., BIANCHI, S., LONGANESI, L., & ZANINI, M. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.06.034 · Cited by 247 · cited 14×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundInfluential
Research works printed but not linked: 1
- Harding AE Sweeney MG Govan GG Riordan-Eva P Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation Am J Hum Genet 1995 57 77 86 7611298 PMC1801226
Cited by
Items 401–500 of 574
Takano, F., Ueda, K., Kurimoto, T., Arai, M., Nagai, T., Yamada‐Nakanishi, Y., & Nakamura, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-89076-z · Cited by 1
Clinical Review of Neuro-ophthalmology: Part I
AlRyalat, S. A., Ryalat, A. T., Laylani, N. A. R., & Lee, A. G. (2025) · Springer eBooks · doi:10.1007/978-981-96-1517-9_3 · Cited by 2
Takano, F., Kitamura, M., Ueda, K., & Nakamura, M. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.05.006 · Cited by 1
“Known triggers include heavy smoking and alcohol consumption, 30 antibiotic use or trauma, 31,32 and sex hormone in fl uences.”
Iorga, R. E., Moraru, A. D., Dănulescu, R. M., Urdea, D., & Danielescu, C. (2025) · Life · doi:10.3390/life15081172 · Cited by 1
“Many studies suggested that idebenone is an effective and safe treatment for these patients [25,26,28].”
Smolar, A. L. O., Viswanath, R., Bomze, H. M., Ying, H., Stinnett, S. S., & Gospe, S. M. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.2.6 · Cited by 1
“4,5 Gene therapy trials have aimed to restore normal complex I function in RGC mitochondria by using adeno-associated virus to deliver wild type versions of mutated mitochondrial genes, thus far limited to two genes, mtND4 and mtND1 .”
Kang, E. Y.-C., Tseng, Y.-J., Peng, W.-H., Hung, H.-C., Lin, P.-H., Montales, K. P., Sherman, E. A., Peregrin, J., Wang, E. H.-H., Kang, C., et al. (2026) · Science Advances · doi:10.1126/sciadv.adx7815 · Cited by 3
“Previous research has shown that idebenone, which bypasses defective Complex I and acts as an antioxidant, is a promising candidate that is currently an approved therapy for LHON ( 74 , 75 ).”
Nair, A. P., Aishwarya Janaki, P., Janani, G., Abishek kumar, B., Vellingiri, B., & Subramaniam, M. D. (2026) · Acta Histochemica · doi:10.1016/j.acthis.2026.152331 · Cited by 1
Varrassi, G., Tran, Y. V., Farì, G., Encinas, M. N., Corriero, A., Puntillo, F., Pham, P. V., & Leoni, M. L. G. (2026) · Antioxidants · doi:10.3390/antiox15080948 · Cited by 3
Advances in therapeutic strategies for Leber’s hereditary optic neuropathy
Karanjia, R., & Sadun, A. A. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1098531 · Cited by 1
Leber's hereditary optic neuropathy: Report of a simple case associated with a rare variant mutation
Malhotra, R. M., Mejally, M. A. A., Abualela, H., & Eltemamy, M. (2016) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.194314 · Cited by 1
Finsterer, J., & Zarrouk‐Mahjoub, S. (2017) · Clinical ophthalmology · doi:10.2147/opth.s136761 · Cited by 1
Emerging Treatments for Leber's Hereditary Optic Neuropathy and Other Genetic Causes of Visual Loss
Bakaeva, T. V., Mallery, R. M., & Prasad, S. (2019) · Seminars in Neurology · doi:10.1055/s-0039-3399504 · Cited by 1
Ueda, K., Kurimoto, T., Takano, F., Murai, Y., Mori, S., Sakamoto, M., Nagai, T., Yamada‐Nakanishi, Y., & Nakamura, M. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-048814 · Cited by 1
(2013) · Neuro-Ophthalmology · doi:10.3109/01658107.2013.767119 · Cited by 1
Sperl, W., & Freisinger, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-41814-3_18 · Cited by 1
Goumalatsou, C. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0001 · Cited by 1
Leberjeva hereditarna optična nevropatija – pregled bolezni z analizo prisotnosti v Sloveniji
Šega, R., Burgar, J., Fakin, A., Pajić, S. P., Volk, M., Hawlina, M., Glavač, D., & Jarc-Vidmar, M. (2022) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3234 · Cited by 1
Mitochondria-targeted antioxidants: coenzyme Q10, mito-Q and beyond
López‐Lluch, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90256-4.00013-8 · Cited by 2
Liu, J., Li, Q., Peng, T., Zhou, Q., He, B., & Zhu, B. (2022) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/s-0042-1756500 · Cited by 1
Currently available therapies in mitochondrial disease
Kornblum, C., Lamperti, C., & Parikh, S. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-12-821751-1.00007-5 · Cited by 2
Leber’s hereditary optic neuropathy: clinical and genetic analysis of Bulgarian patients
Cherninkova, S., Zaharova, B., Kamenarova, K., Mihova, K. Y., Atemin, S., Todorov, T., Haykin, V., Oscar, A. H., Tournev, I., Kaneva, R. P., et al. (2023) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2023.2255073 · Cited by 1
“Randomized, multicenter, double-blind and placebo-controlled studies have shown good efficacy and safety of oral Idebenone [39–44].”
BackgroundMigräne und mitochondriale Erkrankungen
Hämmerl, L., & Kraya, T. (2023) · Der Schmerz · doi:10.1007/s00482-023-00764-z · Cited by 1
Hassan, A. K., Mohsen, M., & Serhan, H. A. A. (2024) · Neuro-Ophthalmology · doi:10.1080/01658107.2024.2360413 · Cited by 1
Morgia, C. L., Klopstock, T., & Yu‐Wai‐Man, P. (2024) · EMJ Neurology · doi:10.33590/emjneurol/nowg1634 · Cited by 1
Self-citationCalame, D. G., & Goldstein, A. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-10944-7.00064-0 · Cited by 1
Sergott, R. C., Carelli, V., Newman, N. J., Biousse, V., Yu‐Wai‐Man, P., Vignal‐Clermont, C., Josse, C., Taiel, M., Sahel, J., Barboni, P., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.9.42 · Cited by 2
“15,16 Idebenone therapy is approved in Europe, United Kingdom, Switzerland, and Israel but not by the U.S. Food and Drug Administration.”
Self-citationMitochondrial Cardiovascular Diseases
Keogh, M. J., Steele, H. E., & Chinnery, P. F. (2018) · Springer eBooks · doi:10.1007/978-3-319-66114-8_8 · Cited by 1
Self-citationTreatment of Leber Hereditary Optic Neuropathy
Yu‐Wai‐Man, P., & Lam, B. L. (2019) · Springer eBooks · doi:10.1007/978-3-319-98455-1_14 · Cited by 1
Self-citationLHON – Behandlungsoption trotz schlechtem Ausgangsvisus?
Rickmann, A., Wocker, L., Damm, L.-J., Ivanescu, C., Szurman, P., & Guerra, N. P. (2019) · Der Ophthalmologe · doi:10.1007/s00347-019-0864-8 · Cited by 1
Bhate, M., Kulkarni, S., Nalawade, R., & Pujar, A. (2022) · Journal of Pediatric Ophthalmology & Strabismus · doi:10.3928/01913913-20220124-02 · Cited by 1
Chen, J. J.-W., & Lee, M. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_42 · Cited by 1
Clutton, J. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0008 · Cited by 1
Clutton, J. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0007 · Cited by 1
Myers, G. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0012 · Cited by 1
Therapie mitochondrialer Erkrankungen
Kornblum, C. (2012) · Medizinische Genetik · doi:10.1007/s11825-012-0347-7 · Cited by 1
Pre-hospital emergency medicine
Collingwood, T. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0010 · Cited by 1
Acheson, J. F., Bremner, F., GRAHAM, E. M., Howard, R., Leff, A. P., Plant, G. T., Shorvon, S. D., & Toosy, A. (2016) · doi:10.1002/9781118486160.ch14 · Cited by 1
A synthetic potassium channel reduces oxidative stress via cellular adaptronicsPreprint
Russo, A., Saponaro, A., Trini, S., Nelson, T. S., Allen, H. N., Oddone, R., Villa, C., Torrente, Y., Khanna, R., Porro, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.18.624138 · Cited by 1
An Overview of Leber’s Hereditary Optic Neuropathy
Dalton, M. R. (2015) · The Kabod The Journal of the Liberty University Honors College · doi:10.70623/suqh8897
“Patients have recorded an increase in visual activity shortly after treatment with idebenone [10].”
BackgroundRetinal Neuronal Remodelling in a Model of Optic Atrophy
Williams, P. A. (2011) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 2
Treatment of Leber's Hereditary Optic Neuropathy-An Update
Lin, H.-Z., Huang, S., & Tsai, R. (2014) · 神経眼科 = Neuro-ophthalmology Japan · doi:10.11476/shinkeiganka.31.89
Barboni, P., Savini, G., & Sadun, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-24085-5_10
A Female Patient with Down Syndrome and Low-Penetrance Leber's Hereditary Optic Neuropathy
Frousiakis, S. E., Pouw, A. E., Karanjia, R., & Sadun, A. A. (2014) · Case Reports in Ophthalmology · doi:10.1159/000369612
The sword of Damocles: Leber's hereditary optic neuropathy – patient and clinician perspectives
Smith, M. J., & Bremner, F. (2013) · International Journal of Ophthalmic Practice · doi:10.12968/ijop.2013.4.2.52
Ubiquinone in cardiac arrest: From bathroom to bedside
Damian, M. S., & Hargreaves, I. P. (2012) · Resuscitation · doi:10.1016/j.resuscitation.2012.05.012
Special Issue: The evolving role of mitochondria in metabolism
Schiff, M., Jacobs, H. T., Vockley, J., & Rustin, P. (2012)
Additional New Therapeutic Options
Müller-York, A. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0136b
Idebenone Tested as Treatment for Leber Hereditary Optic Neuropathy
Toro, J. (2011) · Journal watch · doi:10.1056/jn201108300000002
Optical coherence tomography and electrophysiology of the optic nerve head
Beh, S. C., Schnurman, Z., Conger, D. L., Conger, A., Greenberg, B. M., Frohman, E. M., & Frohman, T. C. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139649506.009
Neuropatía óptica hereditaria de Leber: ¿de qué perspectivas terapéuticas disponemos?
Castillo, L., & Arruga, J. (2016) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2016.06.005
Leber hereditary optic neuropathy: What are the therapeutic perspectives?
Castillo, L., & Arruga, J. (2016) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2016.09.008
Leber's hereditary optic neuropathy and epilepsy: a case report
Котов, А. С., Gushchina, E. V., Маtyuk, Y. V., Борисова, М. Н., Пантелеева, М. В., & Shatalin, A. V. (2016) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20161169289-94
Clinical and genotypic aspects of mitochondrial disease
Gorman, G. S. (2015)
Newman, N. J. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000471
“In the double-blind, randomized controlled trial of idebenone vs placebo in the treatment of LHON (Rescue of Hereditary Optic Disease Outpatient Study, RHODOS (16)), patients with vision loss up to 5 years were treated with 900 mg/d of idebenone for 24 weeks.”
Clinical Reasoning: A 10-year-old boy with bilateral vision loss
Bulwa, Z. B., Nichols, J., & Gupta, N. (2017) · Neurology · doi:10.1212/wnl.0000000000004005
Von der isolierten Optikusatrophie zur Multisystemerkrankung
Klotz, K. A., Lange, C., Lagrèze, W. A., & Kirschner, J. (2017) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-017-0318-9
Drugs acting on mitochondrial pathways
Srinivasan, A., Selvarajan, S., Dkhar, S. A., & Gunaseelan, V. (2017) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20174353
Thulliez, M., Laudier, B., Vignal‐Clermont, C., Hardy, G., & Bonicel, P. (2018) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2018.01.004
Leber’s Hereditary Optic Neuropathy
Wang, A.-G. (2018) · Springer eBooks · doi:10.1007/978-981-10-7668-8_7
A Middle-aged Woman With Vision Loss and Cecocentral Scotoma
Jacobi, J. E., Leavitt, J. A., & Chen, J. J.-W. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.0077
Wang, L., Li, X., Xiao, Y., Li, L., Zhang, T., & Liao, L. (2018) · Journal of Clinical & Experimental Ophthalmology · doi:10.4172/2155-9570.1000759
“the color vision and contrast sensitivity was improved significantly [7-9].”
BackgroundThe Genetics of Leber’s Hereditary Optic Neuropathy: A Literature Review
Liu, H. (2018) · University of Ottawa Journal of Medicine · doi:10.18192/uojm.v8i2.3846
Wahłsten, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812832-9.00011-7
Outcome Measures and Quality of Life in Mitochondrial Diseases
Koene, S., Jimenez‐Moreno, C., & Gorman, G. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-05517-2_19
Aktuelle Aspekte bei mitochondrialen Erkrankungen
Klopstock, T., & Freisinger, P. (2019) · Nervenheilkunde · doi:10.1055/a-0884-4517
“[19] Klopstock T, Yu-Wai-Man P, Dimitriadis K.”
BackgroundSelf-citationKumar, S., Ghosh, S., Choudhary, N., Faruq, M., Inderganti, P. K., Singh, V., Saran, R. K., Sait, H., & Kapoor, S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/724872
Advances in treatment of inherited metabolic disorders with neurological symptomatology
Magner, M., Kolářová, H., & Honzík, T. (2018) · Neurologie pro praxi · doi:10.36290/neu.2018.085
Shih, G. C., & Brooks, B. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00143-9
New therapeutics to modulate mitochondrial energy metabolism in neurodegenerative disorders
Orsucci, D., Ienco, E. C., Siciliano, G., & Mancuso, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819621-2.00023-1
Özer, P. A. (2021) · Bulgarian Review of Ophthalmology · doi:10.14748/bro.v65i1.7429
Steventon, N. B. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780192888501.003.0005
Baldwin, A., & Myers, G. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0015
Mitochondriale Erkrankungen: Was Sie für die Praxis wissen müssen
Klopstock, T. (2021) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-021-1821-z
Self-citationNeuro-Ophthalmology in Medicine
Prasad, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819306-8.00024-1
労働・貧困・社会保障(3)福祉国家の胎動と『ベヴァリッジ報告』
唐鎌, 直. (2009) · 労働法律旬報
Treatment and Management of Hereditary Metabolic Myopathies
Vorgerd, M., & Deschauer, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71317-7.00023-8
Genetic disorders affecting the optic nerve
(2022) · Elsevier eBooks · doi:10.1016/b978-0-12-813944-8.00015-9
Wang, M. Y., Sadun, A. A., & Chan, J. W. (2014) · Springer eBooks · doi:10.1007/978-1-4614-0691-4_7
Chen, J. J.-W., & Lee, M. S. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_42-1
Karanjia, R., Yu‐Wai‐Man, P., & Newman, N. J. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_45-1
Self-citationGordon, L. K. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_19 · Cited by 2
Arianayagam, S. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0006
Baldwin, A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0013
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0006
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0004
Buckley, S. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0003
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0002
Jandeck, C., Rüther, K., & Schulz, É. (2014) · Elsevier eBooks · doi:10.1016/b978-3-437-23076-9.00017-6
Chinnery, P. F., & Turnbull, D. M. (2020) · doi:10.1093/med/9780198746690.003.0612
Self-citationBaldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0008
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0003
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0001
Baldwin, A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780192888501.003.0014
Kidd, D. P. (2017) · Neurodegeneration · doi:10.1002/9781118661895.ch18
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0009
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0012
Mitochondrial disorders due to mutations in the nuclear genome
Chinnery, P. F., & Horváth, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00028-3
Self-citationBaldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0014
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0010
Metadata
- Authors
- Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., Kernt, M., Petraki, D., Rummey, C., Leinonen, M., Metz, G., Griffiths, P. G., Meier, T., & Chinnery, P. F.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- 2 Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Foundation Hospital, NE1 4LP, NHS Trust, UK
- Centre Hospitalier de l’Université de Montréal (CA)
- Royal Victoria Infirmary (GB)
- Santhera Pharmaceuticals (Switzerland) (CH)
- 8 4Pharma, Stockholm, 16440 Kista, Sweden
- Corresponding author
- Chinnery, Patrick F.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07-23
- Volume
- 134
- Issue
- 9
- Pages
- 2677-2686
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3170530
- OpenAlex
- W2124154990
- Cited by
- 578
- References
- 32
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 41 · 2023: 36 · 2022: 44 · 2021: 42 · 2020: 69 · 2019: 39 · 2018: 31 · 2017: 28 · 2016: 61 · 2015: 28 · 2014: 28 · 2013: 29 · 2012: 29
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Wellcome Trust (01GM0862)
- National Institute for Health and Care Research (NF-SI-0509-10011)
- Parkinson's UK
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung (01GM0862)
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- idebenone, Leber's hereditary optic neuropathy, mitochondrial DNA mutations, mitochondrial disease, visual acuity, retinal nerve fiber layer thickness, treatment response heterogeneity, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Aged, Antioxidants, DNA, Mitochondrial, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Placebos, Prospective Studies, Retina, Ubiquinone, Visual Acuity, Contrast Sensitivity, Optic Atrophy, Hereditary, Leber, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.